An Exploratory Study Of Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation Determined By Different Molecular Diagnostic Methods
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Jul 2016 Planned End Date changed from 1 Dec 2014 to 1 Mar 2017.
- 20 Jul 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016.
- 20 Jul 2016 Status changed from discontinued to active, no longer recruiting.